Karuna Therapeutics
A clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.
The company's lead product candidate is KarXT, an M1/M4-preferring muscarinic agonist, which has the potential to offer a unique and mechanistically differentiated treatment option for schizophrenia and psychosis in Alzheimer's disease.
The firm announced positive top-line results in March 2023 from the Phase III EMERGENT-3 trial of KarXT, in schizophrenia. Shortly after it also announced a public stock offering, with the goal of raising $400 million.
Latest Karuna Therapeutics News & Features
12 March 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze